American Association for Cancer Research

sorry, we can't preview this file

cd-20-1826_supplementary_materials_and_methods_suppsm1.docx (16.14 kB)

Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

Download (16.14 kB)
journal contribution
posted on 2023-04-04, 00:02 authored by Ravikanth Maddipati, Robert J. Norgard, Timour Baslan, Komal S. Rathi, Amy Zhang, Asal Saeid, Taku Higashihara, Feng Wu, Angad Kumar, Valli Annamalai, Saurav Bhattacharya, Pichai Raman, Christian A. Adkisson, Jason R. Pitarresi, Maximilian D. Wengyn, Taiji Yamazoe, Jinyang Li, David Balli, Michael J. LaRiviere, Tuong-Vi C. Ngo, Ian W. Folkert, Ian D. Millstein, Jonathan Bermeo, Erica L. Carpenter, John C. McAuliffe, Maja H. Oktay, Rolf A. Brekken, Scott W. Lowe, Christine A. Iacobuzio-Donahue, Faiyaz Notta, Ben Z. Stanger
Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma




Albert Einstein Cancer Center

Ruth L. Kirschstein T32

Canadian Institutes of Health Research

Cancer Research Society

Penn Center for Molecular Studies in Digestive and Liver Diseases



The degree of metastatic disease varies widely among patients with cancer and affects clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multifluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC)—a tumor type in which most patients present with metastases. Genomic and transcriptomic analysis revealed an association between metastatic burden and gene amplification or transcriptional upregulation of MYC and its downstream targets. Functional experiments showed that MYC promotes metastasis by recruiting tumor-associated macrophages, leading to greater bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically in metastatic patients. Collectively, these results implicate MYC activity as a major determinant of metastatic burden in advanced PDAC. Here, we investigate metastatic variation seen clinically in patients with PDAC and murine PDAC tumors and identify MYC as a major driver of this heterogeneity.This article is highlighted in the In This Issue feature, p. 275

Usage metrics

    Cancer Discovery





    Ref. manager